BeyondSpring Inc. (BYSI) Shareholder/Analyst Call Prepared Remarks TranscriptSeeking Alpha · Oct 13, 2026
BeyondSpring Wins FDA Fast Track for Plinabulin Lung Cancer ProgramDefense World · Oct 4, 2026
BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC TranscriptSeeking Alpha · Sep 29, 2026
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim AnalysisGlobeNewsWire · Sep 29, 2026
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire · Aug 14, 2026BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.54 | -$0.02 | Beat |
| May 13, 2026 | -$0.54 | -$0.05 | Beat |
| Mar 25, 2026 | -$0.54 | -$0.05 | Beat |
| Nov 12, 2025 | – | -$0.05 | |
| Aug 13, 2025 | – | -$0.04 | |
| May 12, 2025 | – | -$0.06 |